

PRESS RELEASE

QUALIBLOOD SA PARTNERS WITH IMMUNEED AB TO DRIVE INNOVATION AND GROWTH IN DRUG DEVELOPMENT

Liège, Belgium, 20th November 2024 **QUALIblood SA**, a Belgian Contract Research Organization, providing services in the area of preclinical and clinical research is pleased to announce a strategic partnership with **Immuneed AB**, a Swedish specialised Service Provider in non-clinical research.

This collaboration marks a significant milestone in both companies' missions to drive innovation, efficiency, and value for their customers and stakeholders.

Through this partnership, **QUALIblood SA** and **Immuneed AB** will leverage their respective strengths to bring new capabilities to the market, combining the specific strengths and technologies of both companies, e.g., specialised expertise in whole-blood assays, human-relevant immunological assessment, inflammatory markers, dynamic coagulation and fibrinolysis activation evaluation or drug-induced hemolysis. Together, the companies aim to address key challenges in the pre-clinical and clinical drug development phases while offering complementary solutions to the customers. By having access to each partner's services, the customer can combine needed assays in one project and thereby have a streamlined process supported by highly qualified expertise.

"Our partnership with Immuneed AB represents a shared vision for the future of Drug Development," said Julie Winand, CEO of QUALIblood SA. "By combining our resources and expertise, we will be able to deliver a more comprehensive offering that meets the diverse needs of our clients, from enhanced blood profiling to cutting-edge immune response analysis."

QUALIblood SA's expertise in blood investigation, providing bioanalytical support to pharmaceutical companies and research institutions engaged in drug development aligns seamlessly with **Immuneed AB's** commitment to supporting drug developers with human-relevant immunological assessments for preclinical-stage molecules, creating a unique opportunity for mutual growth and advancement.

"We are thrilled to partner with QUALIblood SA to deliver more advanced and scalable solutions to our customers," said Camilla Oldgren CEO of Immuneed AB. This collaboration enables us to expand our offerings in ways that weren't earlier possible, setting a new standard in Drug Development for innovation, quality, and customer satisfaction."

The partnership will include customer referrals, combined studies and co-marketing where applicable.

About Immuneed AB

Immuneed AB is a specialised service provider supporting drug developers with human-relevant immunological assessments for preclinical-stage molecules. With access to fresh human blood from local donors, Immuneed's expert team performs comprehensive studies, analysing how a drug impacts the adaptive and innate immune response, including immune cells, the complement system, cytokines, platelets, and immunoglobulins, and interprets the results. This approach provides drug developers with precise, human-relevant data to support safer, more effective drug development throughout the preclinical phase.

Immuneed AB has a strong commitment to accelerate the journey of bringing life-changing medicines to patients. We do so by providing technology-driven services to pharmaceutical and biotechnology companies worldwide.

With a drive, curiosity, and knowledge, combined with a unique test system, ID.Flow®, Immuneed enable future innovative therapies as only Immuneed can, transforming ideas into life-saving drugs.

For more information, visit www.immuneed.com

About QUALIblood SA

QUALIblood is a contract research organisation specialised in blood investigations, providing bioanalytical support to pharmaceutical companies and research institutions engaged in drug development.

With over ten years of expertise in thrombosis and hemostasis, QUALIblood offers an in-depth analysis of the coagulation activation, fibrinolysis system activation and hemolysis induced by drugs under development. Their expert team manages every aspect of the project, offering customised solutions from supplying necessary biological material to conducting assays and analysing results. This comprehensive package provides essential, high-quality data necessary to assess the coagulation and hemocompatibility of a compound, a requirement to support safe and effective drug development during the preclinical stage.

QUALIblood SA is dedicated to advancing precision in blood analysis, providing reliable, high-quality testing solutions that support research, clinical trials, and regulatory compliance. Our commitment is to empower clients with accurate data and innovative tools that enhance decision-making in healthcare and life sciences.

For more information, visit www.qualiblood.eu